Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H
Blood. 1987 Jun;69(6):1712-20.
We found a novel platelet aggregating factor in a patient with steroid-responsive immune thrombocytopenic purpura that is associated with defective collagen-induced platelet functions. The aggregating factor and platelet functions were analyzed. The patient, a 58-year-old female, had purpura and prolonged bleeding time despite adequate platelet counts (greater than 140,000/microL) after steroid therapy. The patient's platelets responded normally to all agonists except collagen. Platelet adhesion to collagen fibrils was decreased. The patient's plasma induced irreversible aggregation and ATP release in normal platelet-rich plasma (PRP). This platelet aggregating factor was found in F(ab')2 fragments of the patient's IgG, which caused thromboxane B2 synthesis, elevation of cytoplasmic Ca2+ levels, and phosphorylation of 40 kDa protein in normal platelets. Platelet aggregation by the patient's IgG was inhibited by prostacyclin, dibutyryl cAMP, diltiazem, disodium ethylenediaminetetraacetate, and antimycin A plus iodoacetate, but ADP scavengers, cyclo-oxygenase inhibitors, and heparin had little or no effect. The aggregating activity of the patient's IgG absorbed to and eluted from normal platelets. The patient's Fab fragments did not induce platelet aggregation in eight of ten normal PRP but specifically inhibited aggregation induced by collagen and by the patient's IgG. The major component of an immunoprecipitate made with the patient's IgG from radiolabeled membrane proteins of normal platelet extract had a 62 kDa mol wt, while no such precipitate appeared in extracts of the patient's platelets. These results indicated that platelet aggregation by the patient's IgG was induced by the reaction of an antibody with a specific antigen on the normal platelet membrane through stimulus-response coupling. This antigen may be a collagen receptor on the platelet, most likely a polypeptide of 62 kDa under reducing condition. The defect of collagen-induced aggregation of the patient's platelets seemed to be due to alteration of the membrane protein related to this putative collagen receptor.
我们在一名患有类固醇反应性免疫性血小板减少性紫癜的患者中发现了一种新型血小板聚集因子,该因子与胶原蛋白诱导的血小板功能缺陷有关。对该聚集因子和血小板功能进行了分析。该患者为一名58岁女性,尽管在类固醇治疗后血小板计数充足(大于140,000/微升),但仍有紫癜且出血时间延长。患者的血小板对除胶原蛋白外的所有激动剂反应正常。血小板与胶原纤维的黏附减少。患者的血浆在正常富含血小板血浆(PRP)中诱导不可逆聚集和ATP释放。在患者IgG的F(ab')2片段中发现了这种血小板聚集因子,它可导致正常血小板中血栓素B2合成、细胞质Ca2+水平升高以及40 kDa蛋白磷酸化。患者IgG诱导的血小板聚集受到前列环素、二丁酰cAMP、地尔硫䓬、乙二胺四乙酸二钠以及抗霉素A加碘乙酸的抑制,但ADP清除剂、环氧化酶抑制剂和肝素几乎没有影响。患者IgG吸附于正常血小板并从其洗脱后的聚集活性。患者的Fab片段在十份正常PRP中的八份中未诱导血小板聚集,但能特异性抑制胶原蛋白和患者IgG诱导的聚集。用患者IgG从正常血小板提取物的放射性标记膜蛋白制备的免疫沉淀物的主要成分分子量为62 kDa,而在患者血小板提取物中未出现此类沉淀物。这些结果表明,患者IgG诱导的血小板聚集是通过抗体与正常血小板膜上的特定抗原反应,经刺激 - 反应偶联而发生的。该抗原可能是血小板上的胶原受体,在还原条件下最可能是一种62 kDa的多肽。患者血小板胶原蛋白诱导聚集的缺陷似乎是由于与这种假定的胶原受体相关的膜蛋白改变所致。